glp-1 news october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 Drugs: 2025 Pulse Survey

Microglial GLP-1R activation in the TNC may suppress the central sensitization of CM by regulating TNC microglial activation via the PI3K/Akt pathway

Weight loss is associated with a decrease in PsO severity and improved quality of life (QoL).41,42 Weight loss greater than 5% is associated with a higher rate of minimum disease activity in patients who are obese or overweight and in treatment for PsO.43,44 The Mediterranean diet, which facilitates weight loss, reduces psoriatic lesions.45 Weight loss in patients with HS leads to a notable decrease in the number of lesions and, in some cases, disease remission.46 Dysfunctional adiposity has been associated with worse indices of CVR and Dermatology Quality of Life Index (DLQI) in patients with HS.47 The decrease in fatty tissue is associated with a decrease in molecular mechanisms that characterize the systemic inflammatory state.48 Diet and exercise are the first therapeutic step but these interventions are, however, often insufficient to achieve favorable outcomes in skin diseases, good response to treatment for these conditions, and a decrease in CVR

They slow gastric emptying, increase satiety, act on appetite signaling in the brain, and enhance glucose-dependent insulin secretion

Recent Industry Developments FDA Approval of Oral Wegovy and Orforglipron (Regulatory): On December 22, 2025, the FDA approved the first oral GLP-1 specifically for chronic weight management (the Wegovy pill), which launched in January 2026